DK3295954T3 - Middel til anvendelse ved intestinal fruktoseintolerans - Google Patents

Middel til anvendelse ved intestinal fruktoseintolerans Download PDF

Info

Publication number
DK3295954T3
DK3295954T3 DK17196121.2T DK17196121T DK3295954T3 DK 3295954 T3 DK3295954 T3 DK 3295954T3 DK 17196121 T DK17196121 T DK 17196121T DK 3295954 T3 DK3295954 T3 DK 3295954T3
Authority
DK
Denmark
Prior art keywords
agent
fructose
fructose intolerance
intestinal fructose
intestinal
Prior art date
Application number
DK17196121.2T
Other languages
English (en)
Inventor
Daniel Henry Wyrobnik
Isaac Harry Wyrobnik
Original Assignee
Vitacare Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39628203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3295954(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitacare Gmbh & Co Kg filed Critical Vitacare Gmbh & Co Kg
Application granted granted Critical
Publication of DK3295954T3 publication Critical patent/DK3295954T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52Isomerases (5)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06Enzymes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/99Oxidoreductases acting on the CH-OH group of donors (1.1) with other acceptors (1.1.99)
    • C12Y101/99011Fructose 5-dehydrogenase (1.1.99.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01026Beta-fructofuranosidase (3.2.1.26), i.e. invertase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y503/00Intramolecular oxidoreductases (5.3)
    • C12Y503/01Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01005Xylose isomerase (5.3.1.5)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK17196121.2T 2007-02-20 2008-02-20 Middel til anvendelse ved intestinal fruktoseintolerans DK3295954T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007008664.6A DE102007008664B4 (de) 2007-02-20 2007-02-20 Mittel zur Anwendung bei Fructoseintoleranz
EP10010195.5A EP2289352B1 (en) 2007-02-20 2008-02-20 Agent for use in the case of fructose intolerance

Publications (1)

Publication Number Publication Date
DK3295954T3 true DK3295954T3 (da) 2019-01-02

Family

ID=39628203

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10010195.5T DK2289352T3 (da) 2007-02-20 2008-02-20 Middel til anvendelse i tilfælde af fructoseintolerans
DK08707777.2T DK2124640T3 (da) 2007-02-20 2008-02-20 Glucoseisomerase til anvendelse i behandlingen af fruktoseintolerans
DK17196121.2T DK3295954T3 (da) 2007-02-20 2008-02-20 Middel til anvendelse ved intestinal fruktoseintolerans

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10010195.5T DK2289352T3 (da) 2007-02-20 2008-02-20 Middel til anvendelse i tilfælde af fructoseintolerans
DK08707777.2T DK2124640T3 (da) 2007-02-20 2008-02-20 Glucoseisomerase til anvendelse i behandlingen af fruktoseintolerans

Country Status (17)

Country Link
US (11) US8460911B2 (da)
EP (5) EP3456342B1 (da)
AT (1) ATE485832T1 (da)
CA (3) CA2984999A1 (da)
CY (1) CY1120085T1 (da)
DE (2) DE102007008664B4 (da)
DK (3) DK2289352T3 (da)
ES (4) ES2783989T3 (da)
HR (2) HRP20100733T1 (da)
HU (2) HUE041311T2 (da)
IL (1) IL200517A (da)
LT (1) LT2289352T (da)
PL (4) PL2124640T3 (da)
PT (3) PT2289352T (da)
RS (1) RS51896B (da)
SI (2) SI2289352T1 (da)
WO (1) WO2008101672A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090060956A1 (en) * 2005-11-23 2009-03-05 Daniel Henry Wyrobnik Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
DE102007008664B4 (de) 2007-02-20 2021-07-29 Vitacare Gmbh & Co. Kg Mittel zur Anwendung bei Fructoseintoleranz
SI2340035T1 (sl) * 2008-09-04 2014-12-31 Sciotec Diagnostic Technologies Gmbh Zdravljenje melabsorbcije fruktoze
GB201417386D0 (en) 2014-10-01 2014-11-12 Nofima As Sugar-depleted fruit or vegetable juice product, method of producing the same and use thereof to maintain health and treat and to prevent medical ailments
FI127298B (en) 2016-06-23 2018-03-15 Fazer Ab Oy Karl An enzyme with fructan hydrolase activity
EP3793684A4 (en) 2018-04-18 2022-01-26 Baylor College of Medicine Development of amyloglucosidase as a medicinal food or dietary supplement
EP3924486A4 (en) * 2019-02-14 2022-12-07 Gutsybio Inc. LIVING BIOTHERAPEUTICS FOR THE TREATMENT OF CARBOHYDRATE DISORDERS
CA3186646A1 (en) * 2020-07-23 2022-01-27 Anjie Liu Food supplement composition to aid in digestion of fructan, mannitol, and sorbitol

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083A (en) * 1849-02-06 Cooking-stove
GB1455993A (en) 1973-01-12 1976-11-17 Novo Industri As Glucose isomerase
US4396602A (en) 1981-09-22 1983-08-02 Asahi Kasei Kogyo Kabushiki Kaisha Blood glucose level lowering agents
SE8505783D0 (sv) 1985-12-06 1985-12-06 Rolf Bergkvist Forfarande for framstellning av livsmedelsprodukter och dessas anvendning
US5436003A (en) * 1994-02-10 1995-07-25 Triarco Industries, Inc. Method of alleviating gastrointestinal distress with a composition containing beta-fructofuransidase, cellulase and hemi-cellulase
DK1077609T3 (da) 1998-05-13 2008-10-20 Novozymes Inc Metode til anvendelse af cellobiose dehydrogenase i bagning
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
JP2000125883A (ja) * 1998-10-21 2000-05-09 Internatl Reagents Corp フルクトキナーゼ及びその遺伝子
AU6326699A (en) 1998-11-05 2000-05-29 Novozymes A/S Methods for using a glucose isomerase in baking
WO2000047236A1 (en) 1999-02-12 2000-08-17 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
MXPA02008447A (es) 2000-03-01 2002-12-13 Nestle Sa Formulacion de carbohidrato (adyuvante prebiotico) para el mejoramiento de la respuesta inmune.
US6646394B2 (en) 2001-07-09 2003-11-11 Nissan Motor Co., Ltd. Control device for plurality of rotating electrical machines
US20030113310A1 (en) 2001-12-17 2003-06-19 Van Laere Katrien Maria Jozefa Method for the treatment of obesity, overweight and fluctuations in blood insuline and/or glucose levels
US7067124B2 (en) 2003-03-28 2006-06-27 National Enzyme Company Protease composition and method for treating a digestive disorder
EP3318271A1 (en) * 2005-11-16 2018-05-09 Pro Natura Gesellschaft für Gesunde Ernährung mbH Agent for use in the case of fructose intolerance
DE102006013624B4 (de) 2005-11-23 2012-03-15 Pro Natura Gesellschaft für gesunde Ernährung mbH Mittel zur Anwendung bei Fructoseintoleranz
US20090060956A1 (en) 2005-11-23 2009-03-05 Daniel Henry Wyrobnik Agent for reducing the useable calorie content of food and for therapeutic reduction of weight, in particular for use in the case of adiposity (obesity)
WO2007059956A1 (en) * 2005-11-23 2007-05-31 Pro Natura Gesellschaft für gesunde Ernährung mbH Agent for use in the case of disorders of blood sugar metabolism, including diabetes
US20090214620A1 (en) 2005-11-23 2009-08-27 Pro Natura Gesellschaft Fuer Gesunde Ernaehrung Mb Agent for use in the case of disorders of blood sugar metabolism, including diabetes
DE102007008664B4 (de) 2007-02-20 2021-07-29 Vitacare Gmbh & Co. Kg Mittel zur Anwendung bei Fructoseintoleranz
US20090060656A1 (en) 2007-08-28 2009-03-05 Allied Tube & Conduit Corporation Paver edging device and method

Also Published As

Publication number Publication date
US8460911B2 (en) 2013-06-11
US9155786B2 (en) 2015-10-13
CA2890721C (en) 2018-01-09
EP2124640B1 (en) 2010-10-27
US20190282678A1 (en) 2019-09-19
IL200517A (en) 2016-06-30
EP2289352B1 (en) 2017-11-29
US20130202695A1 (en) 2013-08-08
US20160243207A1 (en) 2016-08-25
EP2124640A2 (en) 2009-12-02
EP3456342A1 (en) 2019-03-20
DE602008003199D1 (de) 2010-12-09
US20170319668A1 (en) 2017-11-09
SI2289352T1 (en) 2018-03-30
PL3295954T3 (pl) 2019-02-28
EP2289352A3 (en) 2011-05-25
DK2289352T3 (da) 2018-02-12
EP3295954B1 (en) 2018-09-12
HUE10010195T2 (hu) 2018-07-30
DE102007008664A1 (de) 2008-08-21
DK2124640T3 (da) 2011-01-31
DE102007008664B4 (de) 2021-07-29
US20240335517A1 (en) 2024-10-10
US20130202696A1 (en) 2013-08-08
ES2783989T3 (es) 2020-09-21
PL2289352T3 (pl) 2018-04-30
ES2356357T3 (es) 2011-04-07
CA2716421A1 (en) 2008-08-28
WO2008101672A3 (en) 2009-06-18
RS51896B (sr) 2012-02-29
US11826406B2 (en) 2023-11-28
HRP20180219T1 (hr) 2018-04-06
IL200517A0 (en) 2010-04-29
US20180169197A1 (en) 2018-06-21
ES2700675T3 (es) 2019-02-18
US11147861B2 (en) 2021-10-19
US20130202694A1 (en) 2013-08-08
HRP20100733T1 (hr) 2011-02-28
ATE485832T1 (de) 2010-11-15
PL2124640T3 (pl) 2011-04-29
US10842854B2 (en) 2020-11-24
PT2289352T (pt) 2018-03-09
US20090311232A1 (en) 2009-12-17
PT3295954T (pt) 2018-12-17
EP2289352A2 (en) 2011-03-02
HUE041311T2 (hu) 2019-05-28
CA2984999A1 (en) 2008-08-28
LT2289352T (lt) 2018-02-26
US9119860B2 (en) 2015-09-01
US20220072111A1 (en) 2022-03-10
CA2716421C (en) 2015-07-21
EP3456342B1 (en) 2020-01-22
US9289474B2 (en) 2016-03-22
WO2008101672A2 (en) 2008-08-28
PT2124640E (pt) 2011-01-13
CA2890721A1 (en) 2008-08-28
EP3693005A1 (en) 2020-08-12
CY1120085T1 (el) 2018-12-12
SI2124640T1 (sl) 2011-03-31
EP3295954A1 (en) 2018-03-21
US20130302411A1 (en) 2013-11-14
ES2658123T3 (es) 2018-03-08
PL3456342T3 (pl) 2020-06-15

Similar Documents

Publication Publication Date Title
DK3295954T3 (da) Middel til anvendelse ved intestinal fruktoseintolerans
AU2007221366A8 (en) Oxyntomodulin derivatives
CL2012001103A1 (es) Método para reducir el nivel del polipéptido tau desacetilado en una célula, que comprende poner en contacto la célula con un agente que incrementa la actividad de un polipéptido que desacetila tau y/o un agente que disminuye la actividad de un polipéptido que acetila tau; y usos terapéuticos para tratar una tauopatía.
UA98629C2 (ru) Соединения и способ модуляции киназ
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
WO2011011642A3 (en) Biphasic and dynamic adjustable support devices and methods with assist and recoil capabilities for treatment of cardiac pathologies
KZ24152B (en) Method of photosensitizer activation, treatment method with application of activated photosensitizer and photosensitizer application to prepare medicine
ATE518010T1 (de) Aktive oberflächengekoppelte polymerasen
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
TNSN08400A1 (en) Organic compounds and their uses
WO2009019294A3 (en) Bupropion hydrobromide and therapeutic applications
EP2300599A4 (en) INCREASING THE EFFECTIVENESS OF CELL THERAPY, INCLUDING TREATMENT WITH ALPHA-1-3-FUCOSYLTRANSFERASE
WO2008066784A3 (en) Expression of foxp3 by cancer cells
CY1119940T1 (el) Παραγοντας για χρηση στην περιπτωση δυσανεξιας στη φρουκτοζη
NO20085032L (no) Aminotiazoler og deres anvendelser
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
WO2013025751A3 (en) Urethral catheter tension holding and movement stabilizing devices
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough
IL185807A0 (en) Use of amino-substituted benzimidazoles
WO2009007112A3 (en) Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction
WO2008008507A3 (en) Methods of treatment of diabetes